Basking Ridge, NJNCT03587844Now EnrollingIRB Ready

Mycosis Fungoides Clinical Trial in Basking Ridge, NJ

Access cutting-edge mycosis fungoides treatment through this phase 2 clinical trial at a research site in Basking Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Basking Ridge location

Preparing your pre-screening questions…

Expert Care in Basking Ridge

Access mycosis fungoides specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mycosis fungoides treatment provided free

Apply for This Basking Ridge Location

Check if you qualify for this mycosis fungoides clinical trial in Basking Ridge, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Basking Ridge

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Basking Ridge site if eligible
  4. 4Begin participation

About This Mycosis Fungoides Study in Basking Ridge

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Mycosis fungoides (MF) and Sezary Syndrome (SS)
Pathologically confirmed mycosis fungoides/sezary syndrome at the enrolling institution, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher ° CD30 negative mycosis fungoides patients are eligible.
Age ≥ 18 years
ECOG Performance Score ≤ 2
For Cohort 1, patients who have not received brentuximab vedotin are eligible.
For Cohort 2, patients who have previously had brentuximab vedotin for MF/SS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2.
Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment. ° See section 6.2 Subject

Exclusion Criteria

for guidelines regarding adjuvant and maintenance therapy for prior malignancy.
Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering, after discussion with PI.
If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \>200 within 7 days prior to C1D1.
Females of childbearing potential must be on acceptable form of birth control per instutional standard. Lymphomatoid papulosis (LyP)
Pathologically confirmed lymphomatoid papulosis at the enrolling institution
Requiring systemic treatment per investigator's discretion
Age ≥ 18 years
ECOG Performance Score ≤ 2
Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.
Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering.
If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \>200 within 7 days prior to C1D1.
Females of childbearing potential must be on acceptable form of birth control per institutional standard Exclusion Criteria:
Concurrent use of other systemic anti-cancer agents or treatments for mycosis fungoides/sezary syndrome, or lymphomatoid papulosis.
Grade 2 or greater neuropathy
Severe renal impairment (CrCL \<30 mL/min)
Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C) ° See Appendix E for Child Pugh Classification chart
Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with treating provider.
Previous use of brentuximab vedotin (for Cohort 1 ONLY)
Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma).
Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator.
Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.
For Cohort 2, patients who previously progressed on the standard 1.8mg/kg dose and schedule of brentuximab vedotin are ineligible.
A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Basking Ridge?

Yes, this clinical trial (NCT03587844) has an active research site in Basking Ridge, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mycosis Fungoides Treatment Options in Basking Ridge, NJ

If you're searching for mycosis fungoides treatment options in Basking Ridge, NJ, this clinical trial (NCT03587844) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Basking Ridge research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced mycosis fungoides specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mycosis fungoides clinical trials near you to find additional studies recruiting in your area.

More Osteogenesis Imperfecta Trials in Basking Ridge, NJ

See all osteogenesis imperfecta clinical trials recruiting in Basking Ridge — not just this study.

Browse Osteogenesis Imperfecta Trials in Basking Ridge →

Browse More Trials by Condition

Osteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Basking Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Basking Ridge, NJ